Abstract
Aims To develop a new intraocular lens (IOL) power selection method with improved accuracy for general cataract patients receiving Alcon SN60WF lenses.
Methods and Analysis A total of 5016 patients (6893 eyes) who underwent cataract surgery at University of Michigan’ s Kellogg Eye Center and received the Alcon SN60WF lens were included in the study. A machine learning-based method was developed using a training dataset of 4013 patients (5890 eyes), and evaluated on a testing dataset of 1003 patients (1003 eyes). Each eye had a complete profile of preoperative biometry, the implanted IOL power, and postoperative refraction. The performance of our method was compared to that of Barrett Universal II, Haigis, Hoffer Q, Holladay 1, and SRK/T.
Results MAE of the Nallasamy formula in the testing dataset was 0.312 Diopters (MedAE = 0.242 D). Performance of existing methods were as follows: Barrett Universal II MAE = 0.328 D (MedAE = 0.256 D), Haigis MAE = 0.363 D (MedAE = 0.289 D), Hoffer Q MAE = 0.404 D (MedAE = 0.331 D), Holladay 1 MAE = 0.371 D (MedAE = 0.298 D) and SRK/T MAE = 0.376 D (MedAE = 0.300 D). The Nallasamy formula performed significantly better than all five existing methods based on the paired Wilcoxon test with Bonferroni correction (p-value < 0.05).
Conclusions Nallasamy formula outperformed the five methods studied (including Barrett Universal II) on overall MAE and MedAE, percentage of eyes within 0.5 D of prediction, as well as MAE in short, medium, and long axial length eyes.
SYNOPSIS Nallasamy formula, a novel machine learning-based IOL power calculation formula developed based on a dataset of 6893 eyes, achieved significantly better prediction accuracy than five traditional IOL power formulas including Barrett Universal II.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Lighthouse Guild, New York, NY (JDS) and National Eye Institute, Bethesda, MD, 1R01EY026641-01A1 (JDS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of the University of Michigan gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are not publically available.
